Industry stalwart leads the nanotechnology pioneer to accelerate growth strategy.
leon-nanodrugs GmbH (“leon”), the Munich based nanotechnology drug development company, has announced Andrea Cusack as its new Chief Executive Officer (CEO) and Managing Director. Cusack joined the company in 2018 from Catalent as Business Development and Licensing Director and in 2019 became Chief Business Officer. During this tenure, she led leon’s successful series B investment round with Christian Nafe, leon’s CFO.
A multi-award winner, with 30 years’ experience in the industry including multiple director positions, Cusack’s extensive track record includes disease management profiling, project management and extensive deal negotiation with in and out licensing transactions with some of the industry’s largest companies.
Dr Hubert Birner, Managing Partner TVM Life Science Management GmbH and Chairman of leon’s board, said: “Andrea has been invaluable since joining leon two years ago and we are very fortunate to have her with us. This is a company with significant ambitions and a desire to make genuine and lasting change in the healthcare industry. Andrea’s technical experience plus her background in licensing and business development make her the best person for this role. Her leadership has helped leon in the past months to complete the series B financing successfully and to enter into substantial new partnerships.”
Andrea Cusack said: “leon is a company like no other and it is a privilege to be appointed as CEO. We have had two successful investment rounds, which signifies confidence in what we’re doing, and this is a very exciting time as we look to accelerate growth with our world-class network partners to deliver more nano formulation solutions to the pharmaceutical industry.”
leon delivers novel, validated and optimized solutions that create value for clients and provide better outcomes for their patients. It expedites API’s to deliver enhanced bioavailability, increased solubility and improved stability, revitalizes forgotten formulations and breathes new life into generics.